Skip to main content
. 2024 Apr 17;30(13):2693–2701. doi: 10.1158/1078-0432.CCR-23-3567

Figure 1.

Figure 1.

FAP-IL2v PK profile on cycles 1 and 5 (A), exposure and effects of ADA development (B), and PD effects in peripheral blood (paired samples) following weekly administration (C). *, P < 0.01. ABS, absolute; AUC, area under the concentration curve; BL, baseline; C, cycle; D, day; NS, not significant.